Accidental Falls/prevention & control; Bone Density/drug effects/physiology; Bone Density Conservation Agents/pharmacology/therapeutic use; Bone and Bones/drug effects/metabolism/physiopathology; Calcitriol/metabolism; Fractures, Bone/drug therapy/physiopathology/prevention & control; Humans; Hydroxycholecalciferols/pharmacology/therapeutic use; Muscle, Skeletal/drug effects/metabolism; Osteoporosis/drug therapy/physiopathology/prevention & control; Vitamin D Deficiency/drug therapy/physiopathology/prevention & control
Abstract :
[en] Established osteoporosis in older patients of both sexes is characterized by decoupled bone remodelling induced by sex hormone deficits and by somatopause, but also by lack of vitamin D and reduced synthesis of the D-Hormone (calcitriol; 1.25 (OH)2D) in the kidneys and bone, as well as from lack of receptors and/or receptor affinity for D-Hormone in the target organs. Parallel to the decreased bone strength a loss of muscle power occurs, together with an increase in balance disorders and an increasing risk of "intrinsic", nonsyncopal locomotoric falls. In alfacalcidol therapy, D-Hormone is provided to the body in circumvention of its own regulation, by means of which higher hormone concentrations can be achieved in the target tissues than by administration of plain vitamin D. In vitro and in vivo experiments have provided growing evidence that D-Hormone analogs tend to normalize PTH, lead to an increase in the number and activity of osteoblasts, reduce the activity of osteoclasts, and might thus normalize the "high bone turnover" in elderly osteoporotic patients ("supercoupling"). In addition, it has been shown that D-Hormone analogs are able to increase muscle power and walking distance in elderly D-Hormone deficient patients. Besides the known effect on the vertebral fracture rate, new clinical data confirm that D-Hormone analogs might reduce peripheral fractures by reducing falls. The expanded understanding of the pathogenesis of glucocorticoid- induced osteoporosis with its disturbed calcium homeostasis and the pharmacological effects of alfacalcidol, which counteract such iatrogenic bone loss, contribute to the understanding of its clinical efficacy in this most frequent form of secondary osteoporosis. Due to its recently discovered immunomodulating properties, alfacalcidol might find a slot in the management of bone loss caused by chronic inflammatory diseases or by organ transplantations. Alfacalcidol has multifactorial effects, among which the best known are its anti-bone loss and anti-fracture efficacies in postmenopausal osteoporosis. This demonstrated efficacy is related to its involvement in bone remodelling, leading to an improved bone strength. Its mode of action on muscle power, which reduces falls, is unique, differentiating this form of therapy from all other anti-osteoporotic drugs, none having demonstrated any influence on falls.
Disciplines :
General & internal medicine
Author, co-author :
Schacht, E.
Richy, F.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Language :
English
Title :
The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures.
Publication date :
2005
Journal title :
Journal of Musculoskeletal and Neuronal Interactions
Ford AB. Reducing the threat of hip fracture. AM J Public Health 1989; 79:269-270.
Mosekilde L. Vertebral structure and strength in vivo and in vitro. Calcif Tissue Int 1993; 53:S121-S126.
Runge M, Schacht E. Multifactorial pathogenesis of falls as a basis for multifactorial interventions. J Musculoskel Neuronal Interact; 2005 (in press).
Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 1995; 332:556-561.
Ferrucci L, Penninx BW, Leveille SG, Corti MC, Pahor M, Wallace R, Harris TB, Havlik RJ, Guralnik JM. Characteristics of non-disabled older persons who perform poorly in objective tests of lower extremity function. J Am Geriatr Soc 2000; 48:1102-1110.
Nordin BEC, Need AG, Morris, HA, Horowitz M. The special role of "hormonal" forms of vitamin D in the treatment of osteoporosis. Calcif Tissue Int 1999; 65:307-310.
Lau KHW, Baylink DJ. Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 1999; 65:295-306.
Lau KHW, Baylink DJ. Treatment of 1,25(OH)2D3(D-hormone) deficiency/resistance with D-hormone and analogs. Osteologie 2001; 10:28-39.
Schacht E. Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol. Calcif Tissue Int 1999; 65:317-327.
Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct action from estrogen. J Bone Miner Res 2000; 15:770-779.
Shiraishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, Ikeda K, Ogata E. The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int 1999; 65:311-316.
Ito M, Azuma Y, Takagi H, Komoriya K, Ohta T, Kawaguchi H. Curative effect of combined treatment with alendronate and 1α-hydroxyvitamin D3 on bone loss by ovariectomy in aged rats. Jpn J Pharmacol 2002; 89:255-266.
Bischoff HA, Borchers M, Gudat F, Duermueller U, Theiler R, Stähelin HB, Dick W. In situ detection of 1,25-dihydroxyvitamin D receptor in human skeletal muscle tissue. Histochem 2001; 33:19-24.
Bischoff HA, Stähelin HB, Urscheler N, Ehrsam R, Vontheim R, Perrig-Chiello P, Tyndall A, Theiler R. Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil 1999; 80:54-58.
Sörensen OH, Lund BI, Saltin B, Lund BJ, Andersen RB, Hjorth L, Melson F, Mosekilde F. Myopathy in bone loss of ageing: improvement by treatment with 1-alpha-hydroxycholecalciferol and calcium. Clinical Science 1979; 56:157-161.
Verhaar HJJ, Samson MM, Jansen PAF, de Vreede PL, Manten JW, Duursma SA. Muscle strength, functional mobility and vitamin D in older women. Aging Clin Exp Res 2000; 12:455-460.
Scharla SH, Schacht E, Bawey S, Kamilli I, Holle D, Lempert UG. Pleiotropic effects of alfacalcidol in elderly patients with rheumatoid arthritis, arthritis + rheuma 2003; 23:268-274.
Gallagher JC, Fowler SE, Detter JR, Sherman SS. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 2001; 86:3618-3628.
Gallagher JC. The effects of calcitriol on falls and fractures and physical performance tests. J Steroid Biochem Mol Biol 2004; 89-90:497-501.
Dukas L, Bischoff HA, Lindpaintner LS, Schacht E, Birkner-Binder D, Damm TN, Thalmann B, Stähelin HB. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc 2004; 52:230-236.
Sato Y, Maruoka H, Oizumi K. Amelioration of hemiplegia-associated osteopenia more than 4 years after stroke by 1α-hydroxyvitamin D3 and calcium supplementation. Stroke 1997; 28:736-739.
Sato Y, Manabe S, Kuno H, Oizumi K. Amelioration of osteopenia and hypovitaminosis D by 1α-hydroxyvitamin D3 in elderly patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 66:64-68.
Wong M. Raloxifene does not affect neuromuscular-related risk factors for falling or the incidence of falls in postmenopausal women with osteoporosis. J Am Geriatr Soc 2000; 48:S44.
McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344;333-340.
Wolf SL, Barnhart HX, Kutner NG, McNeely E, Coogler C, Xu T. Reducing frailty and falls in older persons: an investigation of Tai Chi and computerized balance training. Atlanta FICSIT Group. Frailty and Injuries: Co-operative Studies of Intervention Techniques. J Am Geriatr Soc 1996; 44:489-97.
Hayashi Y, Fujita T, Inoue T. Decrease of vertebral fracture in osteoporotics by administration of 1alpha-hydroxyvitamin D3. JBMR 1992; 10:50:184-188.
Orimo H, Shiraki M, Hayashi Y, Hoshino T, Onaya T, Miyazaki S, Kurosawa H, Nakamura T, Ogawa N. Effects of 1-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994; 54:370-376.
Tilyard MW, Spears GF, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992; 326:357-362.
Tanizawa T, Imura K, Ishii Y, Nishida S, Takano Y, Mashiba T, Endo N, Takahashi HE. Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: a retrospective study. Osteoporos Int 1999; 9:163-170.
Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N, Cranney A, Adachi J, Tugwell P, Josse R, Greenwood C, Guyatt G. The Osteoporosis Methodology Group, and the Osteoporosis Research Advisory Group. Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23:560-569.
Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. The Osteoporosis Methodology Group, and the Osteoporosis Research Advisory Group. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocrine Reviews 2002; 23:570-578.
Richy F, Ethgen O, Bruyere O, Reginster J-Y. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004; 15:301-310.
Godschalk M, Levy RJ, Downs RW. Glucocorticoids decrease vitamin D receptor numbers and gene expression in human osteosarcoma cells. J Bone Miner Res 1992; 7:21-27.
Ebert R, Jovanovic M, Ulmer M, Schneider D, Meibner-Weigl J, Adamski J, Jakob F. Down-regulation by nuclear factor kB of human 25-hydroxyvitamin D3 1α-hydroxylase promoter. Mol Endocrinol 2004; 18:2440-2450.
Oelzner P, Muller A, Deschner F, Huller M, Abendroth K, Hein G, Stein G. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 1998; 62:193-198.
Lempert UG, Minne HW, Albrecht B, Scharla SH, Matthes F, Ziegler R. 1,25-dihydroxyvitamin D3 prevents the decrease of bone mineral appositional rate in rats with inflammation-mediated osteopenia (IMO). Bone Miner 1989; 7:149-158.
DeLuca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J 2001; 15:2579-2585.
Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trends Mol Med 2002; 8:174-179.
Cantorna MT, Woodward WD, Hayes CE, DeLuca HF. 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-β1 and IL-4. J Immunol 1998; 160:5314-5319.
Cantorna MT, Hayes CE, DeLuca HF. 1,25-dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998; 128:68-72.
Andelkovic Z, Vojinovic J, Pejnovic N, Popovic M. Immunomodulatory effects of high oral dose Alpha D3 in rheumatoid arthritis patients. Rheum Eur 1996; 25:33.
Lemire J. 1,25-Dihydroxyvitamin D3 - a hormone with immunomodulatory properties. Z Rheumatol 2000; 59:24-27.
Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, Tugwell P, Gordon M, Steele M, Webber C, Goldsmith CH. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year follow up. J Rheumatol 1996; 23:995-1000.
Reginster JY, Kuntz D, Verdickt W, Wouters M, Guillevin L, Menkes CJ, Nielsen K. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999; 9:75-81.
Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J, Speer G, Bossanyi A. Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 2000; 59:48-52.
Van Cleemput J, Daenen W, Geusens P, Dequeker J, van de Werf F, VanHaecke J. Prevention of bone loss in cardiac transplant recipients. Transplantation 1996; 61:1495-1499.
Sambrook PN, Henderson NK, Keogh A, Macdonald P, Glanville A, Spratt P, Bergin P, Ebeling P, Eisman J. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 2000; 15:1818-1824.
Shane E, Addesso V, Namerow P, McMahon D, Lo S, Staron R, Zucker M, Pardi S, Maybaum S, Mancini D. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 2004; 350:767-776.
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001; 44:1496-1503.
Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 2004; 24:63-70.
Van Staa TP, Leufkens HGM, Abenhaim A, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15:993-1000.
Van Etten E, Branisteanu DD, Overbergh L, Bouillon R, Verstuyf A, Mathieu C. Combination of a 1,25-dihydroxyvitamin D3 analog and a bisphosphonate prevents experimental autoimmune encephalomyelitis and preserves bone. Bone 2003; 32:397-404.
Shibata T, Shira-Ishi A, Sato T, Masaki T, Sasaki A, Masuda Y, Hishiya A, Ishikura N, Higashi S, Uchida Y, Saito M, Ito M, Ogata E, Watanabe K, Ikeda K. Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res 2002; 17:622-629.
Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN, Eisman JA, Nicholson GC. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium and alendronate plus calcium. J Bone Miner Res 2003; 18:919-924.
Cappola AR, Xue QL, Ferrucci L, Guralnik JM, Volpato S, Fried LP. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab 2003; 88:2019-2025.
Endo I, Inoue D, Mitsui T, Umaki Y, Akaike M, Yoshizawa T, Kato S, Matsumoto T. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 2003; 144:5138-5144.
Boland R. Role of vitamin D in skeletal muscle function. Endocr Rev 1986; 784:434-448.
Bischoff-Ferrari HA, Borchers M, Gudat F, Dürmüller U, Stähelin HB, Dick W. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res 2004; 19:265-269.
Dukas L, Schacht E, Bischoff HA. Better functional mobility in community dwelling elderly is related to D-hormone serum levels and to a daily calcium intake. Accepted for publication in Journal on Nutrition, Health and Aging 2005.
Dukas L, Schacht E, Mazor Z, Stähelin HB. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min. Osteoporos Int 2005; 16:198-203.
Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB. Effect of vitamin D on falls. JAMA 2004; 291:1999-2006.
Richy F, Schacht E, Bruyère O, Ethgen O, Gourlay M, Reginster JY. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int 2005; 76:176-186.
Ringe JD, Schacht E. Prevention and therapy of osteoporosis: the respective roles of plain vitamin D and alfacalcidol. Rheumatol Int 2004; 24:189-197.
Gayan-Ramirez G, Vanderhoydone F, Verhoeven G, Decramer M. Acute treatment with corticosteroids decreases IGF-I and IGF-2 expression in the rat diaphragm and gastrocnemius. Am J Respir Crit Care Med 1999; 159:283-289.
Argiles JM, Alvarez B, Carbo N, Busquets S, Van Royen M, Lopez-Soriano FJ. The divergent effects of tumour necrosis factor-alpha on skeletal muscle: implications in wasting. Eur Cytokine Netw 2000; 11:552-559.
Grounds MD. Reasons for the degeneration of ageing skeletal muscle: a central role for IGF-1 signalling. Biogerontology 2002; 3:19-24.
Smith H, Anderson F, Raphael H, Crozier S, Cooper C. Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial. Osteoporos Int 2004; 15:S8.
Ma K, Mallidis C, Bhasin S, Mahabadi V, Artaza J, Gonzalez-Cadavid N, Arias J, Salehian. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 2003; 285:363-371.
Briffa NK, Keogh AM, Sambrook PN, Eisman JA. Reduction of immunosuppressant therapy requirement in heart transplantation by calcitriol. Transplantation 2003; 75:2133-2134.
de Nijs RNJ, Jacobs JWG, Algra A, Lems WF, Bijlsma JWJ. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 2004;15:589-602.
Walsmith J, Abad L, Kehayias J, Roubenhoff R. Tumor necrosis factor-α production is associated with less body cell mass in women with rheumatoid arthritis. J Rheumatol 2004; 31:23-29.
Yamato H, Okazaki R, Ishii T, Ogata E, Sato T, Kumegawa M, Akaogi K, Taniguchi N, Matsumoto T. Effect of 24R, 25-dihydroxyvitamin D3 on the formation and function of osteoclastic cells. Calcif Tissue Int 1993; 52:255-260.
Seino Y, Ishizuka S, Shima M, Tanaka H. Vitamin D in bone formation. Osteoporos Int 1993; 3:196-198.
van Driel M, Pols HAP, van Leeuwen JPTM. Osteoblast differentiation and control by vitamin D and vitamin D metabolites. Curr Pharm Des 2004; 10:2535-2555.
Shiraishi A, Higashi S, Okawa H, Ogata E. The effect of 1α(OH)D3 on bone metabolism in parathyroidectomized rats with continuous PTH infusion. Osteoporos Int 1997; 7(Suppl.2):35.
Orimo H. Clinical application of 1α(OH)D3 in Japan. Aktuel Rheumatol 1994; 19(Suppl.):27-30.
